Summary
Russia is considered as one the fastest emerging pharma markets in the world. The demand for drugs and pharmaceuticals in the country has increased over the last few years. This has attracted many pharmaceutical companies from all over the world to come and invest in the sector. In line with this trend, the clinical trial industry in the country has also registered a positive growth over the past few years.
In 2009, the number of clinical trials conducted in the country reached around 577, an increase of 14% over 2006. These numbers are further expected to reach around 700 by 2012 end. The factors promoting this growth largely include high patient recruitment rate, increasing prevalence of diseases, high quality standards of clinical studies and low cost of clinical trials in comparison to American and European countries. The same factors are expected to drive the future industry growth.
The regulatory standard of the clinical trial industry in the country is quite high. The regulatory mandates to adopt GCP standards in the general industry practice and this has improved the quality level of clinical studies and results. Besides, safety issues are also taken care by the regulatory body, which involve patient safety, data safety and accuracy concerns. These measures have significantly strengthened the overall structure of the industry. Besides, these high patient safety standards have also increased the patient enrolment rate in the country in various therapies segments.
"Clinical Trials Market in Russia" provides a prudent analysis of the overall clinical trial industry potential. The report also covers various key clinical research companies and sponsors of clinical studies in the country. This will help our clients in understanding the overall market dynamics. The report will prove useful and work as an investment guide for those clients who are looking to invest in the Russian clinical trial industry or conduct their clinical trials in Russia
Table of Contents
1. Analyst View
2. Research Methodology
3. Russian Clinical Trial Industry-An Overview
4. Key Market Trends
4.1 Niche Therapies Segment
4.2 Emerging Economies
4.3 Improving Regulatory Environment
4.4 Technical Expertise and Quality Practices
5. Industry Performance
5.1 Clinical Trials
5.2 Global Clinical Trial Study
5.3 Trials in Advanced Phases
5.4 Trials under Major Therapy Areas
5.5 Multinational Sponsors
6. Regulatory Environment
7. Clinical Trial Cost Analysis
7.1 Lab Fees
7.2 Hourly Rate of CRO
8. Patient Profile and Recruitment Analysis
8.1 Population
8.2 Disease Profile
8.3 Patient Recruitment
8.4 Patient Recruitment Rate
9. Competitive Landscape
9.1 Quintiles
9.2 PSI Co Ltd
9.3 Clinstar
9.4 Parexel
9.5 ICON
List of Figures:
Figure 5-1: Number of Clinical Trials (2006-2012)
Figure 5-2: Share of Study Type in Clinical Trials (2009)
Figure 5-3: Structure of Clinical Trial Market by Study Type (%), 2009
Figure 5-4: Number of Clinical Trials by Phase (2008 & 2009)
Figure 5-5: Clinical Trials by Therapy Area (%), 2009
Figure 5-6: Share of International Sponsors in Clinical Trials by Phase (2009)
Figure 8-1: Population Breakup by Age Group (%), 2009
Figure 8-2: Share of Population and Clinical Trials by Region
Figure 8-3: Leading Causes of Death (%), 2005 & 2030
Figure 8-4: Number of Patients by Study Phase (%), 2009
List of Tables:
Table 5-1: Number of Clinical Trials by Top Five Sponsors (2009)
Table 5-2: Number of Clinical Trials by Top Five International Study Sponsors (2009)
Table 5-3: Number of Clinical Trials by Top Five Russian Study Sponsors (2009)
Table 7-1: Lab Fees Comparison with UK and US (US$)
Table 7-2: Fees Charged by Local CROs in Comparison to International CROs (US$/Hour)
Table 8-1: Top Ten Russian Regions by Number of Investigative Site
Table 8-2: Patient Recruitment Rate in Top Five Therapeutic Areas
Table 9-1: Quintiles-Strengths & Weaknesses
Table 9-2: PSI Co Ltd-Strengths & Weaknesses
Table 9-3: Clinstar-Strengths & Weaknesses
Table 9-4: Parexel-Strengths & Weaknesses
Table 9-5: ICON-Strengths & Weaknesses
